Article Text
Abstract
Objective We aimed to understand the role of the tyrosine phosphatase PTPN14—which in cancer cells modulates the Hippo pathway by retaining YAP in the cytosol—in fibroblast-like synoviocytes (FLS) from patients with rheumatoid arthritis (RA).
Methods Gene/protein expression levels were measured by quantitative PCR and/or Western blotting. Gene knockdown in RA FLS was achieved using antisense oligonucleotides. The interaction between PTPN14 and YAP was assessed by immunoprecipitation. The cellular localisation of YAP and SMAD3 was examined via immunofluorescence. SMAD reporter studies were carried out in HEK293T cells. The RA FLS/cartilage coimplantation and passive K/BxN models were used to examine the role of YAP in arthritis.
Results RA FLS displayed overexpression of PTPN14 when compared with FLS from patients with osteoarthritis (OA). PTPN14 knockdown in RA FLS impaired TGFβ-dependent expression of MMP13 and potentiation of TNF signalling. In RA FLS, PTPN14 formed a complex with YAP. Expression of PTPN14 or nuclear YAP—but not of a non-YAP-interacting PTPN14 mutant—enhanced SMAD reporter activity. YAP promoted TGFβ-dependent SMAD3 nuclear localisation in RA FLS. Differences in epigenetic marks within Hippo pathway genes, including YAP, were found between RA FLS and OA FLS. Inhibition of YAP reduced RA FLS pathogenic behaviour and ameliorated arthritis severity.
Conclusion In RA FLS, PTPN14 and YAP promote nuclear localisation of SMAD3. YAP enhances a range of RA FLS pathogenic behaviours which, together with epigenetic evidence, points to the Hippo pathway as an important regulator of RA FLS behaviour.
- rheumatoid arthritis
- fibroblast-like synoviocytes
- PTPN14
- YAP
- TGFβ
- Verteporfin
- K/BxN
Statistics from Altmetric.com
Key messages
What is already known about this subject?
Fibroblast-like synoviocytes (FLS) play an important role in the pathogenesis of rheumatoid arthritis (RA). Several signalling pathways are known to be dysregulated in rheumatoid FLS; however, the contribution of the Hippo pathway remains unexplored.
What does this study add?
This study shows that the tyrosine phosphatase PTPN14 and the transcription coactivator YAP, known key players in the Hippo pathway, are dysregulated in RA FLS and can modulate the pathological behaviour of FLS in RA.
How might this impact on clinical practice or future developments?
The study suggests that YAP and potentially other members of the Hippo pathway, which is already being targeted for cancer therapy, could be leveraged as therapeutic targets for novel RA therapies.
Introduction
Fibroblast-like synoviocytes (FLS) in the synovial intimal lining of the joint play a pivotal role in the pathogenesis of rheumatoid arthritis (RA)1–4 through invasion of extracellular matrix, secretion of proinflammation cytokines and production of cartilage-degrading matrix metalloproteases (MMPs).
We previously surveyed the expression of protein tyrosine phosphatases (PTPs) in FLS from patients with RA (RA FLS) and reported that PTPσ, PTPκ and PTPα promote the aggressiveness of RA FLS.5–7 In the same survey, non-receptor protein tyrosine phosphatase 14 (PTPN14, also known as PEZ) was found to be among the most highly expressed PTPs in RA FLS.8
PTPN14 is a ubiquitous phosphatase with nuclear and cytosolic localisation and is frequently mutated in various cancers.9–11 Structurally, PTPN14 includes an N-terminal ‘Band 4.1, ezrin, radixin, moesin homology’ (FERM) domain, a linker region and a C-terminal catalytic PTP domain. The linker contains two PPxY motifs that drive the interaction between PTPN14 and Yes-associated protein (YAP), a tumour-promoting transcription coactivator that is a downstream effector of the Hippo pathway.12 13 In cancer cells, PTPN14 acts as a tumour suppressor via sequestration of YAP in the cytoplasm independent of phosphatase activity.14–17 Among PTPN14 known substrates, protein kinase Cδ (PRKCD) and Ras and Rab interactor 1 (RIN1) are important regulators of endosome-related receptor trafficking, suggesting that PTPN14 activity can modulate surface receptor presenting and recycling.18
PTPN14 has been previously implicated in promoting transforming growth factor β (TGFβ) signalling through the TGFβ receptor,9 19 via an unknown mechanism of action. TGFβ is highly expressed in the RA synovium.20 Although the overall role of TGFβ in RA pathogenesis remains incompletely understood, TGFβ potentiates the proinflammatory action of tumour necrosis factor α (TNF) and interleukin 1β (IL-1) on RA FLS.21
Here, we report that RA FLS display TGFβ-dependent overexpression of PTPN14 when compared with FLS derived from patients with osteoarthritis (OA FLS). We propose that in RA FLS, PTPN14 promotes TGFβ signalling via a YAP-mediated mechanism. In addition, we identify the Hippo pathway and YAP as molecules of interest in RA FLS pathogenic action.
Materials and methods
Further information is available in the online supplementary methods.
Supplemental material
FLS lines: FLS lines were obtained from arthroplasties (UC SAN DIEGO IRB#140175). Each line was derived from discarded synovial tissue from patients with RA or OA undergoing synovectomy or total joint replacement, as previously described.22 The diagnosis of RA conformed to the American College of Rheumatology 1987 revised criteria.23
Antisense oligonucleotide ( ASO ) knockdown: Human FLS were grown to 90% confluence and treated with 2.5 µM morpholino antisense oligonucleotides (ASO) (Gene Tools). ASO was replenished in fresh culture media after 3 days and in serum-starvation media after 6 days.
SMAD reporter a ssays: SMAD reporter assays were performed using the Qiagen’s Cignal SMAD Reporter (luc) kit.
Mice: All animal experiments were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee of the La Jolla Institute (#AP140-NB4) and UC SAN DIEGO (#S16098). C57BL/6 KRN mice were provided by Dr Christophe Benoist (Harvard Medical School, Boston, Massachusetts, USA) and were crossed with NOD mice (Taconic Bioscience) to obtain arthritic offspring (K/BxN mice) whose serum was pooled for use in the K/BxN passive serum-transfer arthritis model.
Statistical a nalysis: Two tailed statistical analyses were performed as indicated in the figure legends using GraphPad Prism software. A comparison was considered significant if p <0.05.
Results
TGFβ-dependent overexpression of PTPN14 in RA FLS
A comparison between FLS from 11 patients with RA and 10 patients with OA revealed that PTPN14 is significantly overexpressed in RA FLS than in OA FLS (p<0.01) (figure 1A). We also detected significantly increased PTPN14 protein levels in five RA FLS lines compared with five OA FLS lines (p<0.01, figure 1B,C). Immunofluorescence (IF) assessment of synovial specimens from patients with RA versus OA showed high expression of PTPN14 in RA (figure 1D). Published data and a survey of ImmGen data suggest that PTPN14 is expressed prominently in stromal cells and poorly in immune cells.24 25 In line with this observation, a comparative assessment of PTPN14 mRNA expression in synovial biopsies from the Pathology of Early Arthritis Cohort (PEAC) -including 87 treatment-naïve patients with RA—showed that PTPN14 was significantly more expressed in biopsies characterised by a prominent or exclusive FLS presence (fibroid)—which showed limited expression of CD3, CD20, CD138 and CD68—markers of T cells, B cells, plasma cells and macrophages, respectively (online supplementary figure 1)—versus biopsies characterised by prominent immune cell infiltration (non-fibroid) (p<0.0001, figure 1E).
Supplemental material
We next examined the effect of growth factors on PTPN14 expression in RA FLS and found that TGFβ1 (TGFβ, 50 ng/mL), but not platelet-derived growth factor (PDGF, 50 ng/mL) stimulation enhances PTPN14 expression in serum-starved RA FLS (p<0.05) (figure 1F). RA FLS exhibit an intrinsic upregulation of the mRNAs for TGFβ (TGFB1), TGFβ receptor I (TGFBR1) and thrombospondin 1 (THBS1, encoding an activator of latent TGFβ26) when compared with OA FLS.27 Since PTPN14 is induced by TGFβ, we assessed whether PTPN14 expression correlates with TGFB1, TGFBR1 and THBS1 in FLS. As shown in figure 1G, the expression levels of PTPN14 positively correlated with TGFBR1 in RA (Spearman γ=0.8455, p<0.01) and OA FLS (Spearman γ=0.8364, p<0.01) and THBS1 in RA FLS (Spearman γ=0.6545, p<0.05) and OA FLS (Spearman γ=0.6727, p<0.05), while there was no correlation between the expression levels of PTPN14 and TGFB1 (data not shown). Inhibition of TGFβ signalling using two selective TGFβRI antagonists SB50512428 and RepSox,29 reduced PTPN14 expression in unstimulated RA FLS (p<0.05, p<0.01, respectively) (figure 1H,I) suggesting that enhanced autocrine stimulation with TGFβ plays a role in the upregulation of PTPN14 in RA FLS. However, additional unknown pathways likely contribute to enhance PTPN14 mRNA and protein levels in RA FLS in vitro and in the rheumatoid joint.
PTPN14 promotes TNFα-stimulated and IL-1β-stimulated MMP production in RA FLS
We next tested whether PTPN14 regulates the response of RA FLS to TNF and IL-1β, critical pathogenic cytokines in RA.30 For knockdown PTPN14 in RA FLS, we treated RA FLS with a cell-permeable antisense oligonucleotide (PTPN14 ASO) targeting exon 4 or a control scrambled ASO. Knockdown of PTPN14 in RA FLS after ASO treatment was confirmed by western blotting (online supplementary figure 2). Knockdown of PTPN14 in RA FLS significantly inhibited TNFα-induced expression of MMP1 (figure 2A left panel) but did not affect expression of MMP3, VCAM1 or IL6 (data not shown). We also noticed that knockdown of PTPN14 significantly reduced the expression of MMP13 in RA FLS (figure 2A right panel and data not shown). The effect of PTPN14 ASO on IL-1β-induced MMP1 induction in RA FLS was non-significant (data not shown). In order to rule out off target effects of PTPN14 ASO, we designed a second ASO targeting PTPN14 exon 2 (PTPN14 ASO 2). Treatment of RA FLS with PTPN14 ASO 2 led to inhibition of TNFα-induced MMP1 and inhibition of MMP13 expression identical to the ones obtained with PTPN14 ASO (online supplementary figure 3). Flow cytometry assessment did not show any effect of PTPN14 deficiency on RA FLS survival (online supplementary figure 4). Knockdown of PTPN14 also did not significantly affect RA FLS migration or invasiveness in response to fetal bovine serum (FBS) or RA FLS attachment to cartilage (figure 2B).
PTPN14 promotes TGFβ signalling in RA FLS
As shown in figure 2A, the effect of PTPN14 knockdown was particularly significant on MMP13, an important collagenase in RA, whose expression is regulated by TGFβ signalling in RA FLS and other cell types.6 31 Due to the proposed role of PTPN14 in TGFβ signalling9 and since TGFβ is known to potentiate the action of TNFα and IL-1β in RA FLS, we hypothesised that the phenotypes observed in RA FLS subjected to PTPN14 knockdown might be at least in part due to blockade of autocrine RA FLS TGFβ signalling. Consistent with this model, inhibition of TGFβRI using SB505124 reduced TNFα-stimulated MMP1 induction and abrogated MMP13 expression in RA FLS (figure 2C). We then assessed whether PTPN14 regulates TGFβ-induced MMP1 and MMP13 expression in RA FLS and found that knockdown of PTPN14 reduced TGFβ-induced expression of MMP13 (figure 2D), while no induction of MMP1 was observed after treatment of RA FLS with TGFβ alone (data not shown).
PTPN14-YAP interaction enhances nuclear YAP-mediated TGFβ-SMAD signalling
We next tried to assess the mechanism of action of PTPN14 in TGFβ signalling. We did not observe alterations in TGFβRI expression in cells treated with PTPN14 ASO (figure 3A). Thus, we examined the role of PTPN14 in intracellular canonical TGFβ signalling, mediated by phosphorylated SMAD complexes, which translocate to the nucleus to regulate transcription of target genes.32 We observed no difference in phospho-SMAD2 (pSer465/467) or phospho-SMAD3 (pSer423/425) levels on TGFβ stimulation between RA FLS treated with control or PTPN14 ASO (data not shown). However, RA FLS treated with PTPN14 ASO showed significantly reduced basal and TGFβ-induced nuclear localisation of SMAD3—but not of SMAD2—when compared with cells treated with control ASO (p<0.05) (figure 3B online supplementary figure 5). MMP13 expression has been shown to be regulated by TGFβ through both canonical SMAD-dependent33 and non-canonical mitogen-activated protein kinase (MAPK)-dependent pathways.31 RA FLS subjected to knockdown of PTPN14 did not display significantly altered phosphorylation of extracellular-regulated kinase (Erk), C-Jun N terminal kinase (JNK), p38 MAPK, MAPK kinase 3 (MKK3), MKK4, MKK6 and MKK7 (data not shown), suggesting that non-canonical TGFβ signalling is unlikely to mediate PTPN14-driven expression of MMP13 in RA FLS.
As described, PTPN14 is known to regulate signalling via phosphatase activity dependent and independent mechanisms. There are four known PTPN14 substrates identified in cancer cell lines: β-Catenin,34 p130Cas,35 PRKCD and RIN1.18 Substrate-trapping double mutated PTPN14 catalytic domain (D1079A/C1121S) was expressed and substrate trapping experiments36 37 were carried out with RA FLS lysates, but none of the identified substrates were pulled down by PTPN14 in RA FLS (data not shown). We thus looked at phosphatase activity-independent regulatory mechanisms. It is well documented that PTPN14 regulates Hippo signalling by forming a complex with YAP.16 17 We confirmed the existence of a PTPN14-YAP physical complex in RA FLS by immunoprecipitation (figure 3C). To assess the mechanism of action of PTPN14 in TGFβ-SMAD signalling, we next examined the effect of PTPN14, a catalytically inactive PTPN14 C1121S mutant and a PTPN14 PPxY motifs Y570F/Y732F mutant —which is unable to bind to YAP15 17—in a SMAD reporter assay in HEK293T cells. Consistent with the observations made in RA FLS, overexpression of PTPN14 in HEK293T cell enhanced SMAD reporter activity on TGFβ stimulation (figure 3D). Mutations of the PPxY motifs significantly reduced the SMAD-enhancing activity of PTPN14 while catalytically inactive (C/S) PTPN14 was as effective as PTPN14 WT at promoting the SMAD reporter activity (figure 3D). These data suggest that PTPN14-mediated promotion of TGFβ-induced SMAD activation depends on the ability of PTPN14 to interact with YAP rather than on the phosphatase activity.
The PTPN14-YAP complex enhances YAP cytosolic localisation in cancer cells.15 Therefore, we asked whether PTPN14 regulates the nuclear localisation of YAP in RA FLS. Immunofluorescence of resting RA FLS showed that >80% YAP was localised to the nucleus in subconfluent (~70% confluent) cells (data not shown). Figure 3E shows that both YAP and PTPN14 were found in resting and TGFβ-stimulated RA FLS nuclear lysates. Immunofluorescence analysis of RA FLS revealed no significant changes in nuclear localisation of YAP in unstimulated vs TGFβ- stimulated and in cells subjected to knockdown of PTPN14 vs cells treated with control ASO (figure 3F online supplementary figure 6A).
In the early embryo, YAP is also known to control TGFβ-signalling by modulating SMAD nuclear/cytosolic distribution.38 In RA FLS, we found that partial knockdown of YAP using an ASO directed against YAP exon 2 modulated TGFβ-induced SMAD3 nuclear translocation in RA FLS (figure 3G online supplementary figure 6B,6C). To further demonstrate that nuclear YAP is important to sustain TGFβ-dependent SMAD signalling, we carried out SMAD reporter assays by expressing YAP in frame with a nuclear localisation sequence (NLS-YAP), which results in exclusive overexpression of YAP in the nucleus. Figure 3H shows that NLS-YAP significantly enhanced TGFβ-induced SMAD reporter activity. We conclude that in RA FLS PTPN14 and YAP promote nuclear recruitment of SMAD3 during TGFβ signalling.
The Hippo pathway displays epigenetic alterations in RA FLS and modulates TNF signalling and invasiveness of RA FLS in vitro
The Hippo pathway has recently emerged as a critical regulator of cancer growth and survival and of multiple important basic cell functions; however, no information is available yet on the role of this pathway in RA FLS. A recent highly integrated analysis of epigenetics marks in RA FLS versus OA FLS has identified multiple pathways that are differentially marked and candidate players in the pathogenic behaviour of rheumatoid FLS.39 We thus interrogated the available RA-FLS and OA-FLS epigenetic database, inclusive of nine marks—six histone modifications (H3K27ac, H3K4me1, H3K4me3, H3K36me3, H3K27me3 and H3K9me3), open chromatin, RNA-seq and DNA methylation—for epigenetic alterations in the Hippo pathway. Applying the same integrative method and pathway analysis described in Ref. 39, we discovered that the ‘Hippo signalling’ pathway was significantly enriched in differential epigenetic marks between RA FLS and OA FLS. As shown in figure 4A, the vast majority of known genes belonging to the Hippo pathway (differentially modified genes are highlighted in magenta in the figure), displayed differences in one or more of 5 histone modification (detailed in figure 4B) and/or open chromatin and/or DNA methylation marks. YAP1 (encoding YAP) was differentially modified in H3K4me1, H3K4me3 and open chromatin regions. Figure 4C shows a genome browser screenshot exemplifying the epigenetic landscape within 300 kb of YAP1 for one representative couple of RA vs OA FLS lines with boxes identifying differentially marked regions.
Since the above-mentioned findings point to YAP as an important pathogenic factor and a potential mediator of PTPN14 action in RA FLS, we next assessed whether inhibition of nuclear YAP functions alters RA FLS behaviour and/or phenocopies the effect of PTPN14 knockdown in RA FLS. We treated RA FLS with the small molecule verteporfin, an FDA approved drug for photodynamic therapy that has been shown to inhibit YAP transcriptional activity in vitro and in vivo.40 In line with the observed effect of PTPN14 knockdown, inhibition of YAP with 1 µM verteporfin in RA FLS inhibited TNFα-induced expression of MMP1 and reduced expression of MMP13. However, verteporfin also inhibited TNF-induced MMP3, VCAM1 and IL-6 expression compared with cells treated with vehicle (figure 4D and online supplementary figure 7). Moreover, treatment with verteporfin dramatically inhibited RA FLS invasiveness in response to FBS (figure 4E), suggesting that YAP promotes RA FLS pathogenic action through transcriptional and potentially other mechanisms that only partially overlap with the mechanisms regulated by PTPN14.
YAP promotes RA FLS invasiveness in vivo and arthritis severity in mice
To further assess whether YAP promotes RA FLS pathogenic behaviour in vivo, we employed the severe combined immunodeficiency (SCID) model of FLS cartilage engraftment.41 In line with the in vitro observations reported in figure 4, daily administration of verteporfin (15 mg/kg) to cartilage and RA FLS-engrafted SCID mice led to a significant (p<0.0001) reduction of in vivo cartilage invasion by RA FLS (figure 5A). In order to further assess the role of YAP in a second synoviocyte-dependent model of RA, we also examined whether treatment with verteporfin affects disease development in the passive K/BxN serum-transfer arthritis model. Figure 5B shows that daily administration of 50 mg/kg verteporfin to K/BxN serum-transferred mice (n=28) led to significant reduction of arthritis severity (p<0.0001) compared with control mice treated with DMSO (n=25). Histological assessment of affected joints showed that verteporfin treatment significantly protected mice from bone erosion, cartilage damage and inflammation (figure 5C and online supplementary figure 8).
Discussion
Here, we report that RA FLS display overexpression of PTPN14, which promotes TGFβ canonical signalling. We provide evidence that promotion of SMAD signalling by PTPN14 depends on the formation of a YAP-PTPN14 complex. Although the exact molecular mechanism through which PTPN14 regulates TGFβ-induced SMAD3 translocation in RA FLS remains to be clarified, we speculate that the PTPN14-YAP complex enhances the ability of nuclear YAP to recruit SMAD3 on TGFβ stimulation. YAP has been shown in other cells types to form a complex with SMAD2/3, which promotes nuclear translocation of SMAD complexes.38 42 Thus, it is possible that a trimolecular PTPN14-YAP-SMAD3 complex is formed in the nucleus of RA FLS. The observation that PTPN14 knockdown only partially recapitulates inhibition of YAP nuclear functions is in line with the fact (evident in figure 3F) that PTPN14 is not necessary for YAP nuclear localisation. The latter is a somehow unexpected finding since in many cancer cell types, the PTPN14-YAP complex prevents nuclear translocation of YAP15 and RA FLS have been likened to tumour-like cells due to their peculiar aggressive features in vitro and in vivo.43 However, the partial overlap between PTPN14-mediated and YAP-mediated signalling in RA FLS might also reflect unknown mechanisms of compensation in cells subjected to knockdown of PTPN14. A limitation of our studies of PTPN14 is that some of the changes observed after knockdown in FLS are modest and further studies—eg, in animals with conditional deletion of PTPN14 in FLS when they become available—are needed to confirm that PTPN14 is involved in the pathogenesis of RA and its hierarchical dominance in disease pathogenesis.
Our data also suggest for the first time that the Hippo pathway and nuclear YAP contribute to the aggressive phenotype of RA FLS. Although our reanalysis of the available dataset showed no differences in Hippo pathway transcript levels in resting RA vs OA FLS, the pathway carries an extensive epigenetic signature in RA FLS, which warrants mRNA and protein expression studies in RA and OA FLS subjected to RA-relevant stimulations and in RA synovium. Furthermore, our in vivo data also point to a potential benefit of YAP inhibition to reduce FLS pathogenesis in RA. Since verteporfin has been shown to ameliorate antigen-induced arthritis in rabbits by inducing apoptosis of inflammatory cells,44 further investigations are warranted to elucidate whether YAP inhibition could also control the immune-mediated arm of RA pathogenesis, thus configuring YAP as a potentially unique target for dual immune and FLS-based RA therapy.
References
Footnotes
AB and DJW contributed equally.
Handling editor Josef S Smolen
Contributors AB, DJW, CP and NB conceived, designed and supervised the research, analysed data and wrote the paper. AB, DJW, RA, MLR, BB, MB, KMD, VZ, CS, MZ, AL, XL, LL, DLB, DH, T-CM, MC, SMS, ML, WW, GF, YK-G contributed to acquisition and/or analysis of data. All authors approved the final version of the paper.
Funding This study was funded in part by the National Institutes of Health (NIH) Grants R01 AR066053 and AI070544 and Department of Defense (DOD) grant # W81XWH-16-1-0751 (to NB). AB and DJW were supported by NIH Training Grant T32 AR064194.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval All animal experiments were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee of the La Jolla Institute (#AP140-NB4) and UC SAN DIEGO (#S16098). The generation and banking of FLS lines from arthroplasties was approved by the UC San Diego IRB (#140175). Ethical approval for the PEAC cohort was granted by the King’s College Hospital Research Ethics Committee (REC 05/Q0703/198).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement There are no additional unpublished data.